Clinical Research Industry Cycles: Understanding the Seasons of Clinical Research
Clinical research industry cycles are not always obvious at first glance. While it may seem that clinical research operates independently of seasons, those who have worked in this industry know it follows distinct rhythms—its own cycles of momentum, slowdown, and renewal. I was reminded of this recently when I noticed Christmas decorations already appearing in stores, even though it felt like April was just yesterday.
On the service provider side of the industry—particularly within Contract Research Organizations (CROs)—time often moves differently. It’s not uncommon to hear that a single month of intense activity, such as closing a database, can feel like “dog years,” aging everyone involved by six months or more.
So, let’s talk about the tempo of clinical research and how its seasonal cycles shape the industry.
The Industry Barometer in Clinical Research Cycles: JP Morgan
One of the clearest indicators of the clinical research industry’s health is the energy surrounding the JP Morgan BioPharma Conference each January. In 2024, the conference felt like a return to the “good old days,” with investors actively committing—or at least signaling intent to commit—capital.
However, that early optimism faded as the year progressed. By Q2, global uncertainty began to weigh heavily on investor confidence, leading many to pause funding decisions. This pattern once again highlighted how quickly momentum can shift in clinical research.
January to June: The Marathon Phase of Clinical Research Industry Cycles
The first half of the year often defines the most demanding phase of clinical research industry cycles, requiring endurance, alignment, and precise execution. The year typically begins slowly. In January, the industry shakes off the cobwebs of the holidays and emerges from a brief hibernation. By February, activity accelerates. Clinical trial plans are finalized, RFPs begin circulating, vendors and partners are selected, and projects officially get underway.
With budgets approved and strategies in place, companies focus on regulatory milestones, stakeholder alignment, and compliance execution. This period also coincides with a packed conference schedule, including JP Morgan, SCOPE, BIO, and DIA.
Much like a marathon, the first half of the year demands endurance, discipline, and careful planning. Hitting mid-year targets is critical, as it sets the tone for the remainder of the year. While demanding, this phase is often one of the most productive periods in clinical research.
Summer Slowdown and Fall Reset in Clinical Research Cycles
As summer arrives, the pace shifts. While clinical research itself never stops, the people behind it take time away. Projects already awarded continue to move forward, but new awards slow noticeably as vacations take priority across pharma, biotech, and medical device companies.
Then comes September. Teams return, inboxes fill, and momentum quickly rebuilds. The industry snaps back into high gear as organizations refocus on objectives and timelines heading into year-end.
Q4: The Sprint to Year-End Pressure in Clinical Research Cycles
The fourth quarter brings its own unique challenge—the sprint. While many pharma and biotech teams wind down for the holidays, those involved in site startup and patient enrollment often feel the most pressure.
There is frequently a push to enroll even a single patient before year-end. This milestone is often tied to commitments made to boards or investors. You can almost picture the scene: a founder, facing investor scrutiny, confidently declaring that the first patient will be enrolled before the year closes.
Despite unforeseen obstacles—protocol amendments, investigator feedback, or new testing requirements—the pressure to meet arbitrary deadlines remains. This dynamic highlights how financial and governance expectations can sometimes overshadow the practical realities of clinical research execution.
Closing Thoughts: Preparing for the Next Cycle
As we look ahead, understanding clinical research industry cycles will be essential for teams planning resources, timelines, and expectations for the year ahead. While challenges such as geopolitical conflict, inflation, and unemployment persist, the conclusion of the U.S. election cycle may bring greater stability.
Now is the time to stretch, recalibrate strategies, and prepare for what promises to be a busy year ahead. Clinical research, like the seasons, moves through cycles of growth, pause, and renewal. From the intensity of Q1 to the reflective planning of year-end, each phase brings its own challenges and opportunities.
With the promise of a brighter 2025, the industry is well-positioned to push forward and embrace the next wave of innovation.
About GLSA
Global Life Sciences Alliance (GLSA) connects biotechs, pharma, CROs, and clinical research sites with the right experts, advisors, and solutions to accelerate development and reduce risk. With a network of more than 200 trusted partners spanning pre-clinical and clinical research, GLSA offers flexible, cost-effective access to specialized expertise and services that support early-stage biotechs, mid-size pharma, and global pharmaceutical companies.
When you need trusted, global resources to accelerate your research, GLSA helps you scale smarter and move you forward with confidence.
To learn how GLSA can support your organization, connect with Denise McNerney or Chris Matheus for a conversation about your goals and challenges.